The study of efficacy of AT1 receptor blocker, olmesartan and calcium antagonists , azelnidipine combination therapy in patients with essential hypertension , diabetic or chronic kidney disease

The study of efficacy of AT1 receptor blocker, olmesartan and calcium antagonists , azelnidipine combination therapy in patients with essential hypertension , diabetic or chronic kidney disease - The study of efficacy of AT1 receptor blocker, olmesartan and calcium antagonists , azelnidipine combination therapy in patients with essential hypertension , diabetic or chronic kidney disease (HARIMAYA study)

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004750

Enrollment

200

Registered

2010-12-18

Start date

2010-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patient with essential hypertension, diabetic or chronic kidney disease

Interventions

It changes from therapy of conventional dose of ARB or CCB to combination therapy of olmesartan (20mg/day) and azelnidipine (16mg/day). Target blood pressure (BP) is under 130/80 mmHg

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with essential hypertension , diabetic or chronic kidney disease. Patients are taking conventional dose of AT1 receptor blocker or calcium antagonists. SBP/DBP > 130/80mmHg Patients who meets the above-mentioned requirement.

Exclusion criteria

Exclusion criteria: SCr > 3.0mg/dl Patient has liver dysfunction. It is a developing patient within six months as for cardiac infarction or the apoplexy. Patient who has possibility of pregnancy or pregnancy. Patient while suckling. Patient who judged that doctor is improper

Design outcomes

Primary

Measure	Time frame
The change from baseline in BP (office blood pressure, home blood pressure) The proportion of patients achieving the BP goal provided by the guideline for the management of hypertension in Japan	—

Secondary

Measure	Time frame
The change from baseline of protein in urine and eGFR	—

Countries

Japan

Contacts

Public ContactKoji Ogata

Kochi Medical School Department of Endocrinology, Metabolism and Nephrology

b08d6b06@s.kochi-u.ac.jp088-880-2343

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026